ETFS Holding Abbvie Inc

 
ETF Quotes for ETFS Holding Abbvie Inc top ^
  • Holdings: Facebook Inc Class A , AbbVie Inc , Kraft Foods Group Inc , Phillips 66 , General Motors Co ,
  • Morningstar Rating: 5 Stars
Sign-up for fpx investment picks

 
News Articles for Abbvie Inc top ^
Andrews & Springer LLC , a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities fraud and breach of fiduciary duty claims against AbbVie, Inc. (NYSE: ABBV) (“AbbVie” or the “Company”). If you currently own shares of AbbVie and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigations/ABBV or contact Craig J.
Sign-up for ABBVIE (ABBV) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating AbbVie Inc. For Potential Securities Fraud and Breach of Fiduciary Duty investment picks
NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present at Credit Suisse 2014 Healthcare Conference investment picks
SALT LAKE CITY, Nov.
Sign-up for Myriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM) investment picks
AbbVie Inc. (ABBV) shares climbed more than 2% in premarket trade Friday, after the biopharma company's third-quarter profit and sales beat estimates.
Sign-up for AbbVie shares up 2% as profit, sales beat estimates investment picks
- Reports Third-Quarter Adjusted EPS of $0.89, Up 8.5 Percent and Well Above the Previous Guidance Range of $0.77 to $0.79; Reports GAAP EPS of $0.31 - Significantly Raises 2014 Adjusted EPS Guidance Range to $3.25 to $3.27 from $3.06 to $3.16 (GAAP EPS Guidance Range is $1.15 to $1.17); 2014 Guidance Excludes Any Potential HCV Revenue - Delivers Revenue of $5.019 Billion, an Increase of 7.8 Percent Over Third-Quarter 2013 (Up 8.3 Percent On an Operational Basis); Revenue Up 13.5 Percent Operationally Excluding Lipid Sales - Revenue Growth Reflects 17.5 Percent Global Sales Growth from HUMIRA (Up 17.8 Percent on an Operational Basis) and Strong Growth from Other Key Products - Continues to Expect U.S. Approval of HCV Combination in 2014; Announced Novel R&D Collaboration with Calico to Develop Medicines for Age-Related Diseases; Further Strengthened Pipeline with Global Collaboration to Develop and Commercialize Duvelisib, PI3K-Inhibitor for Treatment of Cancer
Sign-up for AbbVie Reports Third-Quarter 2014 Financial Results investment picks
By Sue Chang, MarketWatch SAN FRANCISCO (MarketWatch) -- Among the companies whose shares are expected to see active trade in Friday's session are ExxonMobil Corp., Chevron Corp., and AbbVie Inc. ExxonMobil(XOM) is projected to report third-quarter earnings of $1.71 a share, according to a consensus survey by FactSet.
Sign-up for UPDATE: ExxonMobil, Chevron, AbbVie earnings in focus investment picks
Data from 13 accepted abstracts include: - New Results from a Phase 2 Study of Venetoclax (formerly ABT-199/GDC-0199) in Patients with Acute Myelogenous Leukemia (AML) - Several Studies of Elotuzumab in Patients with Multiple Myeloma, Including Final Results from a Phase 1b/2 Study - Results from Phase 1 studies of Duvelisib in Patients with Chronic Lymphocytic Leukemia NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present Data on Investigational Oncology Compounds at the 56th American Society of Hematology Annual Meeting investment picks
NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present at Jefferies 2014 Global Healthcare Conference investment picks
Hedge fund Paulson & Co., headed by billionaire John Paulson, opened a 13 million share position in pharmaceutical maker Abbvie Inc. (ABBV) in the third quarter, valued at $750.9 million as of Sept.
Sign-up for Paulson takes stake in Abbvie, adds to Shire holdings investment picks
- Data include results from a Phase 1 study of ABT-414 as monotherapy and in combination with radiation and/or chemotherapy in patients with newly diagnosed and recurrent/unresectable glioblastoma multiforme - AbbVie will initiate a randomized Phase 2 trial of ABT-414 in patients with glioblastoma multiforme NORTH CHICAGO, Ill.
Sign-up for AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology investment picks
- 37 abstracts evaluating HUMIRA and investigational medicines in rheumatologic diseases - New data presented on ABT-122, an investigational novel protein that targets TNF and IL-17 NORTH CHICAGO, Ill.
Sign-up for AbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA® (adalimumab) investment picks
- In adult patients co-infected with genotype 1 (GT1) hepatitis C virus (HCV) infection and human immunodeficiency virus (HIV) type 1 infection, TURQUOISE-I demonstrated sustained virologic response rates 12 weeks post-treatment (SVR(12)) of 93.5 percent after 12 weeks of treatment and 90.6 percent after 24 weeks of treatment, respectively - In adult liver transplant patients with recurrent chronic GT1 HCV infection and new to treatment after transplantation, CORAL-I demonstrated 97.1 percent SVR rates at 12 and 24 weeks post-treatment after 24 weeks of treatment - CORAL-I results published online today in The New England Journal of Medicine BOSTON , Nov.
Sign-up for AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014 investment picks
- Results demonstrated high response rates in adult chronic hepatitis C genotype 4 patients without cirrhosis - Data underscore AbbVie's commitment to evaluating treatments across a range of patients with chronic hepatitis C virus infection BOSTON , Nov.
Sign-up for AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014 investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs primarily in the infectious disease field, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted positive opinions for AbbVie’s investigational, all-oral, interferon-free treatment of VIEKIRAX™ (a combination of ombitasvir, paritaprevir (ABT-450) and ritonavir) plus EXVIERA™ (dasabuvir), with or without ribavirin (RBV), for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, and VIEKIRAX™ only, with RBV, for patients with genotype 4 (GT4) HCV infection.
Sign-up for Enanta Announces CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir(ABT-450)/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe investment picks
- Major regulatory milestone achieved toward approval in the European Union - Final decision from the European Commission expected in the first quarter of 2015 NORTH CHICAGO, Ill.
Sign-up for CHMP Grants Positive Opinions of AbbVie's VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe investment picks
- AbbVie Presents for the First Time Results from the Venetoclax Phase 2 Program in Acute Myelogenous Leukemia - Study Evaluated Preliminary Efficacy of Venetoclax in 32 Patients with Relapsed/Refractory Acute Myelogenous Leukemia and as Frontline Therapy in Patients Unfit for Intensive Treatment NORTH CHICAGO, Ill.
Sign-up for AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting investment picks
NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present at 33rd Annual J.P. Morgan Healthcare Conference investment picks
NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present at Goldman Sachs Healthcare CEOs Unscripted Conference investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
ETFS Holding Abbvie Inc
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: ETFS Holding Abbott Laboratories  |  Next: ETFS Holding Abengoa SA